150 related articles for article (PubMed ID: 30581091)
41. [A case report: an EML4-ALK positive lung adenocarcinoma diagnosed
with lymphoma previously].
Liu L; Heng W
Zhongguo Fei Ai Za Zhi; 2015 Feb; 18(2):89-91. PubMed ID: 25676402
[TBL] [Abstract][Full Text] [Related]
42. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.
To KF; Tong JH; Yeung KS; Lung RW; Law PP; Chau SL; Kang W; Tong CY; Chow C; Chan AW; Leung LK; Mok TS
J Thorac Oncol; 2013 Jul; 8(7):883-91. PubMed ID: 23625156
[TBL] [Abstract][Full Text] [Related]
43. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
[TBL] [Abstract][Full Text] [Related]
44.
Bastos AU; de Jesus AC; Cerutti JM
Eur J Endocrinol; 2018 Jan; 178(1):83-91. PubMed ID: 29046324
[TBL] [Abstract][Full Text] [Related]
45. Recurrence of lung adenocarcinoma after an interval of 15 years revealed by demonstration of the same type of EML4-ALK fusion gene.
Tsukamoto Y; Kanamori K; Watanabe T; Mikami K; Ieki R; Nakano T; Kajimoto K; Hirota S
Pathol Res Pract; 2014 Dec; 210(12):1112-6. PubMed ID: 25238939
[TBL] [Abstract][Full Text] [Related]
46. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.
Yoneshima Y; Ijichi K; Anai S; Ota K; Otsubo K; Iwama E; Tanaka K; Oda Y; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Apr; 118():36-40. PubMed ID: 29572000
[TBL] [Abstract][Full Text] [Related]
47. Small-cell transformation of
Balla A; Khan F; Hampel KJ; Aisner DL; Sidiropoulos N
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29317428
[TBL] [Abstract][Full Text] [Related]
48. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
49. 5'/ 3' imbalance strategy to detect ALK fusion genes in circulating tumor RNA from patients with non-small cell lung cancer.
Tong Y; Zhao Z; Liu B; Bao A; Zheng H; Gu J; McGrath M; Xia Y; Tan B; Song C; Li Y
J Exp Clin Cancer Res; 2018 Mar; 37(1):68. PubMed ID: 29587818
[TBL] [Abstract][Full Text] [Related]
50. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
Heuckmann JM; Balke-Want H; Malchers F; Peifer M; Sos ML; Koker M; Meder L; Lovly CM; Heukamp LC; Pao W; Küppers R; Thomas RK
Clin Cancer Res; 2012 Sep; 18(17):4682-90. PubMed ID: 22912387
[TBL] [Abstract][Full Text] [Related]
51. Ovarian Metastases from ALK-rearranged Lung Adenocarcinoma: A Case Report and Literature Review.
Sasano H; Sekine A; Hirata T; Iwamoto K; Itou Y; Itani H; Kondou S; Tokui T; Tanigawa M
Intern Med; 2018 Nov; 57(22):3271-3275. PubMed ID: 29984766
[TBL] [Abstract][Full Text] [Related]
52. ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.
Williams AS; Greer W; Bethune D; Craddock KJ; Flowerdew G; Xu Z
Virchows Arch; 2016 Nov; 469(5):533-540. PubMed ID: 27562706
[TBL] [Abstract][Full Text] [Related]
53. A Case of a Pregnant Woman Diagnosed as Having
Komura M; Yagishita S; Nakamura K; Arano N; Takeshige T; Muraki K; Nagashima O; Izumi H; Tomita S; Sasaki S; Takahashi K
In Vivo; 2018; 32(5):1205-1209. PubMed ID: 30150445
[TBL] [Abstract][Full Text] [Related]
54. GPC1-ALK: A novel ALK fusion in a patient with pulmonary sarcomatoid carcinoma.
Xiong L; Li X; Chen D; Li S; Luo L
Lung Cancer; 2021 Jan; 151():104-105. PubMed ID: 33277054
[No Abstract] [Full Text] [Related]
55.
Bulutay P; Vatansever D; Taskiran C; Mericoz CA; Tokat F; Kapucuoglu N; Kulac I
Indian J Pathol Microbiol; 2023; 66(2):392-395. PubMed ID: 37077094
[TBL] [Abstract][Full Text] [Related]
56. A Novel EML6-ALK FBXO11-ALK Double Fusion Variant in Lung Adenocarcinoma and Response to Crizotinib.
Lin H; Ren G; Liang X
J Thorac Oncol; 2018 Nov; 13(11):e234-e236. PubMed ID: 30368418
[No Abstract] [Full Text] [Related]
57. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M
BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405
[TBL] [Abstract][Full Text] [Related]
58. [Association between the ALK Gene Status and the Efficacy of First-line
Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma].
Chen M; Cao H; Ji Y; Mao Y; Shen S; Li X
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):732-736. PubMed ID: 29167001
[TBL] [Abstract][Full Text] [Related]
59. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
60. Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.
Zhao N; Zheng SY; Yang JJ; Zhang XC; Xie Z; Xie B; Su J; Chen ZH; Chen SL; Zhang N; Lou NN; Dong S; Wu YL
Clin Lung Cancer; 2015 Mar; 16(2):e5-9. PubMed ID: 25496960
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]